Virogin Biotech

Virogin Biotech aims to be a global, best-in-class oncolytic virus company that creates impactful drugs for patients of the highest medical need. Our platform technology focuses on creating long-lasting antitumor immunity by capitalizing on a robust, transient antiviral immune response through a synergy with multiple payload expression. Virogin is designing a more potent oncolytic virus, expressing optimized payloads to enhance the systemic antitumor immunity in relapsed/refractory cancers. Led by our leadership team with over 25 years of experience in fundamental research, translational and clinical development of immunotherapy & oncolytic virotherapy, we are determined to bring our novel therapies for relapsed/refractory cancers to market.